about
Ovarian cancer, the coagulation pathway, and inflammationThe hypercoagulable state of malignancy: pathogenesis and current debateAssociation between the rat homologue of CO-029, a metastasis-associated tetraspanin molecule and consumption coagulopathySoluble fibrin inhibits monocyte adherence and cytotoxicity against tumor cells: implications for cancer metastasis.A sequence-specific exopeptidase activity test (SSEAT) for "functional" biomarker discovery.Hematology in palliative medicine.Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparinCancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis.Procoagulant activity of the MC28 fibrosarcoma cell line in vitro and in vivo.Impact of venous thromboembolism and anticoagulation on cancer and cancer survivalAlteration of Antithrombin III and D-dimer Levels in Clinically Localized Prostate Cancer.Changes of the coagulation and fibrinolysis system in malignancy: their possible impact on future diagnostic and therapeutic procedures.The hemostatic system and angiogenesis in malignancy.Arterial and venous thrombosis in cancer patientsAnticoagulant effect of Huisheng Oral Solution in a rat model of thrombosis.Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer.Haemostatic alterations in a group of canine cancer patients are associated with cancer type and disease progression.Tissue factor activity of SW-480 human colon adenocarcinoma cells is modulated by thrombin and protein kinase C activation.Protease-activated receptors in cancer: A systematic review.Thrombin enhances the adhesion and migration of human colon adenocarcinoma cells via increased beta 3-integrin expression on the tumour cell surface and their inhibition by the snake venom peptide, rhodostominHyperhomocysteinemia and the role of B vitamins in cancer.Changes in coagulation and permeability properties of human endothelial cells in vitro induced by TNF-alpha or 5,6 MeXAA.Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model.Differential expression of human tissue factor in normal mammary epithelial cells and in carcinomasCatastrophic antiphospholipid syndrome associated with malignancies (case report and review of the literature).A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality.Incidence and risk factors for pulmonary embolism after primary musculoskeletal tumor surgery.Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs).The role of platelet activation in tumor metastasis.Preoperative peripheral plasma fibrinogen level is an independent prognostic marker in penile cancer.Peripheral arterial ischemic events in cancer patients.Primary prevention of venous thromboembolism.Clinical models and biochemical predictors of VTE in lung cancer.Predisposing factors to post-operative adhesion development.Platelets and cancer angiogenesis nexus.The Pathogenetic Role of Apoptosis in Hypercoagulable States.New insights into the pathogenesis of coagulation dysfunction in acute promyelocytic leukemia.Coexpression of tissue factor and tissue factor pathway inhibitor by human monocytes purified by leukapheresis and elutriation. Response of nonadherent cells to lipopolysaccharide.Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system.Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'.
P2860
Q24816796-E15DC843-AD75-4E32-909F-99AE99E67E73Q28212265-20541D07-9B70-4ED2-873C-EF1EA1D23007Q28564140-9C80F5BC-7402-48E0-A01F-756675CE7EBBQ33254832-2F81F0E5-EC24-47D1-8830-894C20C4A2D1Q33305170-4E12334F-4B8B-466D-9C52-DE0E231589C0Q33364223-5A0DA64B-8144-4A6A-ADFA-5303020A0C0DQ33373462-3724655D-0141-4642-9FF9-229C8004CCE8Q33402499-BD15BE81-E70C-4D18-9345-0DB252A55149Q33490882-6189A89E-B059-4079-95B9-2F84946F520BQ33561203-88C03E29-B53D-4319-9E05-F783D83C79E8Q33792838-5A4A8B67-C68C-4860-AF10-C86EE1B53C35Q34079085-72CFC01B-4039-4D3B-B6D7-C1EA664D30C0Q34425462-0276DD0D-2FF2-4312-9C40-FCAB089365CEQ34635182-8641C884-AAA6-40C3-B206-D09C9593DFBEQ34981190-F6EC20AD-AE41-4F55-B57C-197FD9CE9219Q35763766-A744844D-54FE-4B31-8453-6EFF296BE35AQ35927808-3933641B-2B73-45B5-99CC-447EAB3AE79BQ36115096-7F049631-9739-4015-BED4-74C0FA761A16Q36121203-5AAA8D8F-7392-480D-ACCB-DE6DBA5F38CBQ36134295-B2348F70-E9E0-45F4-B0ED-3D4947142411Q36177626-2B49674B-28B8-4E89-B019-09D3B6E03970Q36291971-C2D0EF21-D8D9-49EE-9926-B13E39FDD8AEQ36417960-5C221729-CE38-4EE8-8C0C-0246FA75E068Q36437481-8EB23E99-F1BA-45B3-9A85-923DA79382FAQ36729464-DEEC5897-1763-45B9-92F5-0708FE0B9217Q37091111-7D685A15-AC46-42BF-B233-910F29C719C1Q37170920-9CCFA4F9-E66C-4176-B4C4-04D1FB07A805Q37216570-BD058378-F4EC-4380-887C-F0C282A6D08FQ37242670-AEAB6006-62E8-4FB0-A336-C1FC80BA3154Q37707101-38CED5C4-74A8-4141-BFB1-29025553274AQ37812994-3C38DB99-A7B9-4840-9A97-B6502DC33217Q37998002-2ECB3087-C98B-4AC5-9F0B-54FA1D182692Q38205701-B21898D3-9A8C-41F3-BEEE-9AE0BF96968EQ38455443-D2F20087-E6BD-402C-8669-D6333F833A5EQ38691783-90EB5F59-C974-4138-B1E6-F31480C3836FQ38897750-2D0C4498-668B-4B0A-9E6C-F89CEC42DBD0Q40771484-24614720-E42F-4BFD-BDFE-81B7823116A3Q40921529-99DC8C62-FE2D-4304-BFC9-87B25138527AQ41500641-1D487A35-B7B1-4C65-A0C5-463F539CF8CFQ43431686-61731C98-85A4-43DD-90EE-79621C3C9DF6
P2860
description
1992 nî lūn-bûn
@nan
1992 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Hemostatic alterations in cancer patients.
@ast
Hemostatic alterations in cancer patients.
@en
type
label
Hemostatic alterations in cancer patients.
@ast
Hemostatic alterations in cancer patients.
@en
prefLabel
Hemostatic alterations in cancer patients.
@ast
Hemostatic alterations in cancer patients.
@en
P2093
P356
P1476
Hemostatic alterations in cancer patients.
@en
P2093
P2888
P304
P356
10.1007/BF01307180
P577
1992-11-01T00:00:00Z